BlackRock Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

BlackRock Advisors’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$36K	Sell	7,827 -932	-11%	-$3.85K	﹤0.01%	3335
2016 Q3	$37K	Buy	8,759 +2,621	+43%	+$8.48K	﹤0.01%	3332
2016 Q2	$15K	Buy	6,138 +3,342	+120%	+$12.1K	﹤0.01%	3517
2016 Q1	$13K	Hold	2,796	–	–	﹤0.01%	3537
2015 Q4	$11K	Sell	2,796 -2,433	-47%	-$11.2K	﹤0.01%	3621
2015 Q3	$20K	Hold	5,229	–	–	﹤0.01%	3518
2015 Q2	$24K	Buy	+5,229	New	+$50.1K	﹤0.01%	3471

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock Advisors's AST Position: Q4 2016 in Review

BlackRock Advisors reduced its Asterias Biotherapeutics Inc. Series A (AST) stake by 11% in Q4 2016, selling an estimated $3.85K and leaving 7,827 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #3335.

BlackRock Advisors first reported a position in AST in Q2 2015 and has held it in 7 quarters since. The position peaked at $37K in Q3 2016. 66 funds tracked by Wall St. Rank hold AST as of Q4 2016.

BlackRock Advisors held 7,827 shares of Asterias Biotherapeutics Inc. Series A worth $36K as of Q4 2016.
BlackRock Advisors sold 932 Asterias Biotherapeutics Inc. Series A shares in Q4 2016, an estimated $3.85K.
Asterias Biotherapeutics Inc. Series A made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3335 holding.
BlackRock Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's Asterias Biotherapeutics Inc. Series A position peaked at $37K in Q3 2016.
66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.